Medical devices, healthcare technology and the business of care
510(k) clearance · K254230

CapsoView (CVV); CapsoCloud (CLD)

CapsoVision, Inc. · Decision date Sep 25, 2026

MEDTECHLEDGER EXPLANATIONK254230

What did the FDA decide?

CapsoVision, Inc. received a substantially equivalent (SESE) decision for K254230 on September 25, 2026, covering CapsoView (CVV) and CapsoCloud (CLD), classified under 21 CFR 876.1540 as gastrointestinal capsule endoscopy analysis software, product code QZF, in the Gastroenterology/Urology specialty. The submission adds AI-assisted reading tools to the existing CapsoCam Plus (SV-3) reading software cleared under K242643, without changes to that hardware. The listed primary predicate is Ankon Technologies' NaviCam ProScan (DEN230027); DigestAID's Deep Capsule (K250655) is listed as a reference device.

The described tools mark suspected abnormal frames with bounding boxes, suggest digestive tract landmarks, and identify obscured frames; results are stored as metadata without altering video frames. The stated indications cover adults and pediatric patients over two years of age imaged for suspected small bowel bleeding, and the summary states the tools do not replace clinician interpretation. The summary notes the patient-population difference from the predicate reflects study populations rather than a difference in intended use. The provided excerpts do not include performance data, so the basis for the equivalence determination is not shown here.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Gastroenterology, Urology
Decision date
Sep 25, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K254230
Regulatory pathway
510(k) premarket notification
Product code
QZF
Decision code
SESE
Decision date
Sep 25, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Gastrointestinal Capsule Endoscopy Analysis Software Device.

Product code
QZF
FDA device class
2

FDA decision timeline

  1. K254230 received

    Application receipt date recorded by FDA.

  2. K254230 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

No additional submissions with a verified PMA or product-code relationship are linked here.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

CapsoVision, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Saratoga, CA

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records